Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Pipeline Review, H2 Pharmaceutical 2016
"Cyclin
Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein
Kinase 2 or CDK2 or EC 2.7.11.22) - Pipeline Review, H2 2016"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Directs, Cyclin Dependent Kinase 2 (p33 Protein Kinase or
Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Pipeline
Review, H2 2016, provides in depth analysis on Cyclin Dependent
Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or
CDK2 or EC 2.7.11.22) targeted pipeline therapeutics.
The report provides comprehensive information on the Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics,
The report provides comprehensive information on the Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics,
its
complete research and development history and latest news and press
releases. Additionally, the report provides an overview of key
players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or
Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted
therapeutics development and features dormant and discontinued
projects.
Global
Markets Directs report features investigational drugs from across
globe covering over 20 therapy areas and nearly 3,000 indications.
The report is built using data and information sourced from Global
Markets Directs proprietary databases, company/university websites,
clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles
featured in the report undergoes periodic review following a
stringent set of processes to ensure that all the profiles are
updated with the latest set of information. Additionally, various
dynamic tracking processes ensure that the most recent developments
are captured on a real time basis.
Scope
-
The report provides a snapshot of the global therapeutic landscape
for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division
Protein Kinase 2 or CDK2 or EC 2.7.11.22)
-
The report reviews Cyclin Dependent Kinase 2 (p33 Protein Kinase or
Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted
therapeutics under development by companies and universities/research
institutes based on information derived from company and
industry-specific sources
-
The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
-
The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental
activities
-
The report reviews key players involved in Cyclin Dependent Kinase 2
(p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC
2.7.11.22) targeted therapeutics and enlists all their major and
minor projects
-
The report assesses Cyclin Dependent Kinase 2 (p33 Protein Kinase or
Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted
therapeutics based on mechanism of action (MoA), route of
administration (RoA) and molecule type
Reasons
to buy
-
Gain strategically significant competitor information, analysis, and
insights to formulate effective R&D strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Identify and understand the targeted therapy areas and indications
for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division
Protein Kinase 2 or CDK2 or EC 2.7.11.22)
-
Identify the use of drugs for target identification and drug
repurposing
-
Identify potential new clients or partners in the target demographic
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Plan mergers and acquisitions effectively by identifying key players
and its most promising pipeline therapeutics
Comments
Post a Comment